

Items supported by the Samaritan Fund

- (a) Non-drug Items supported by the Fund
 - (i) One-off Non-drug Items
 - (ii) Non-one-off Non-drug Items
- (b) Self-financed Drugs supported by the Samaritan Fund (SF) and Community Care Fund (CCF) Medical Assistance Programme (First Phase Programme) (for specified self-financed cancer drugs)

(a) Non-drug Items supported by the Fund

(i) One-off Non-drug Items

*[Financial assessment of the Fund will be based on **patient's household income and asset, with reference to the Median Monthly Domestic Household Income (MMDHI) and the estimated cost / deposit (if applicable) of the item concerned respectively.]***

1. Percutaneous Transluminal Coronary Angioplasty (PTCA) and other consumables for interventional cardiology
2. Cardiac Pacemakers
3. Myoelectric Prosthesis
4. Custom-made Prosthesis
5. Appliances for prosthetic and orthotic services, physiotherapy and occupational therapy services (including prosthesis, wheelchair, mobility & transfer aids, self care aids, therapeutic furniture, and training & treatment device & equipment)
6. Home use equipment and appliances (including hearing devices & accessories, respiratory equipment, communication aids, and infusion pump for enteral/parenteral nutrition)
7. Gamma knife surgery
8. Harvesting of marrow in a foreign country for marrow transplant

(ii) Non-one-off Non-drug Items

*[Financial assessment of the Fund will be based on **patient's household annual disposable financial resources (ADFR).]***

1. Proton Beam Therapy[^]
2. Tumor Treating Fields^{^^}

The Fund will only support the model which can meet the basic medical needs of the patients.

Remarks:

[^] With effect from 20 June 2024.

^{^^} With effect from 25 May 2024.

(b) Drugs supported by the Samaritan Fund

The following specific self-financed drugs are supported by the Samaritan Fund:

Item	Drug	Specialties	Clinical indications
1a	Abatacept	Rheumatology	Rheumatoid arthritis
1b		Paediatrics	Juvenile idiopathic arthritis
2a	Abemaciclib [#]	Oncology	HR positive HER2 negative locally advanced or metastatic breast cancer (MBC)
2b	Abemaciclib [#] and		
3	Fulvestrant		
4	Abiraterone [#]	Oncology	Prostate cancer
5	Abrocitinib [^]	Dermatology [^]	Atopic dermatitis [^]
6a	Acalabrutinib [#]	Haematology	Relapsed / refractory chronic lymphocytic leukaemia (CLL)
6b			Previously untreated chronic lymphocytic leukaemia (CLL) with unmutated IGHV
7a	Adalimumab	Dermatology / Paediatrics	Severe psoriasis
			Hidradenitis suppurativa (acne inversa)
7b		Ophthalmology	Non-infectious intermediate, posterior and panuveitis
7c			Paediatric chronic non-infectious anterior uveitis
7d		Paediatrics	Juvenile idiopathic arthritis
7e		Rheumatology	Ankylosing spondylitis
7f			Psoriatic arthritis
7g			Rheumatoid arthritis
8	Afatinib	Oncology	Non-small cell lung cancer with activating EGFR mutation (first-line treatment)
9a	Aflibercept	Ophthalmology	Neovascular (wet) age-related macular degeneration
9b			Macular oedema secondary to Central Retinal Vein Occlusion
9c			Visual impairment caused by diabetic macular oedema

Item	Drug	Specialties	Clinical indications
10a	Alectinib [#]	Oncology	ALK+ve non-small cell lung cancer (NSCLC) (first-line treatment)
10b			ALK+ve metastatic non-small cell lung cancer (NSCLC), progressed on Crizotinib and intolerant to Ceritinib, or have CNS-progression after Crizotinib
11	Anifrolumab [^]	Rheumatology [^]	Systemic lupus erythematosus (SLE) [^]
12	Apalutamide [#]	Oncology	Prostate cancer
13	Atezolizumab	Oncology	EGFR-ve and ALK-ve metastatic non-small cell lung cancer (NSCLC) progressed on or following platinum-based chemotherapy
14	Axitinib [#]	Oncology	Advanced renal cell carcinoma
15a	Azacitidine	Haematology	Acute myeloid leukaemia (AML)
15b			Chronic myelomonocytic leukaemia (CMML)
15c			Myelodysplastic syndromes (MDS)
16	Baricitinib	Rheumatology	Rheumatoid arthritis
17	Belimumab	Paediatrics / Rheumatology	Systemic lupus erythematosus (SLE)
18	Bendamustine	Haematology	Chronic lymphocytic leukaemia (CLL)
19	Benralizumab	Respiratory Medicine	Severe refractory eosinophilic asthma (add-on treatment)
20a	Bortezomib	Haematology	Multiple myeloma (MM)
21a	Brentuximab Vedotin	Haematology	Systemic anaplastic large cell lymphoma (sALCL)
21b			CD30+ cutaneous T-cell lymphoma (CTCL)
21c			CD30+ Hodgkin lymphoma
22a	Brigatinib [#]	Oncology	ALK+ve non-small cell lung cancer (NSCLC) (first-line treatment)
22b			ALK+ve metastatic non-small cell lung cancer (NSCLC), progressed on Crizotinib and intolerant to Ceritinib, or have CNS-progression after Crizotinib
23a	Canakinumab	Paediatrics	Cryopyrin-associated periodic syndromes

Item	Drug	Specialties	Clinical indications
23b			Familial Mediterranean fever
23c			Hyperimmunoglobulin D syndrome / mevalonate kinase deficiency
23d			Systemic juvenile idiopathic arthritis
23e			Tumour necrosis factor receptor associated periodic syndrome
24	Carfilzomib	Haematology	Multiple myeloma (MM)
25a	Ceritinib [#]	Oncology	ALK+ve non-small cell lung cancer (NSCLC) (first line treatment)
25b			ALK+ve advanced non-small cell lung cancer (NSCLC) previously treated with Crizotinib
26a	Certolizumab Pegol	Rheumatology	Ankylosing spondylitis
26b			Psoriatic arthritis
26c			Rheumatoid arthritis
27	Cetuximab	Oncology	RAS wild-type colorectal cancer
28	Cladribine	Neurology	Relapsing-remitting multiple sclerosis (RRMS)
29a	Crizotinib [#]	Oncology	ALK+ve non-small cell lung cancer (NSCLC)
29b			ROS1-positive non-small cell lung cancer (NSCLC)
30	Dabrafenib [#] and Trametinib [#]	Oncology	Skin cancer
31			
32	Daratumumab and Bortezomib	Haematology	Systemic AL amyloidosis
20b			
33a	Dasatinib	Haematology	Imatinib-resistant chronic myeloid leukaemia (CML)
33b			Imatinib-resistant philadelphia or BCR/ABL positive acute lymphoblastic leukaemia (ALL)
33c			Newly diagnosed chronic myeloid leukaemia (CML) in chronic phase
33d			Nilotinib-resistant chronic myeloid leukaemia (CML)

Item	Drug	Specialties	Clinical indications
34a	Dupilumab	Dermatology / Paediatrics	Atopic dermatitis
34b		Respiratory Medicine	Severe asthma with type 2 inflammation (add-on treatment)
35	Durvalumab	Oncology	Unresectable and stage III non-small cell lung cancer (NSCLC) not progressed following concurrent platinum-based chemotherapy and radiation therapy
36	Specific ultra-expensive drug <i>(The patient must be a permanent resident of the Hong Kong Special Administrative Region according to the Immigration Ordinance)</i>		
	Eculizumab	Haematology	Paroxysmal nocturnal haemoglobinuria (PNH)
37a	Eltrombopag	Haematology	Chronic immune thrombocytopenia (for post-splenectomised patients; or non- splenectomised patients in whom splenectomy is contraindicated)
37b			Severe aplastic anaemia (SAA) [#]
38	Enzalutamide [#]	Oncology	Prostate cancer
39a	Etanercept	Dermatology	Severe psoriasis
39b		Paediatrics	Juvenile idiopathic arthritis
39c		Rheumatology	Ankylosing spondylitis
39d			Psoriatic arthritis
39e			Rheumatoid arthritis
40	Everolimus [#]	Oncology	HR positive HER2 negative advanced breast cancer
41a	Faricimab [^]	Ophthalmology [^]	Neovascular (wet) age-related macular degeneration [^]
41b			Visual impairment caused by diabetic macular oedema [^]
42	Gefitinib	Oncology	Non-small cell lung cancer with activating EGFR mutation (first-line or second-line treatment)
43	Gilteritinib [#]	Haematology	Relapsed or refractory acute myeloid leukaemia (AML)

Item	Drug	Specialties	Clinical indications
44a	Golimumab	Rheumatology	Ankylosing spondylitis
44b			Psoriatic arthritis
44c			Rheumatoid arthritis
45	Growth Hormone	Endocrinology	Dwarfism
46a	Guselkumab	Dermatology	Severe psoriasis
46b		Rheumatology	Psoriatic arthritis
47a	Ibrutinib [#]	Haematology	Relapsed or refractory mantle cell lymphoma (MCL)
47b			Chronic lymphocytic leukaemia (CLL)
48a	Infliximab	Dermatology	Severe psoriasis
48b		Rheumatology	Ankylosing spondylitis
48c			Psoriatic arthritis
48d			Rheumatoid arthritis
49	Inotuzumab Ozogamicin	Haematology	Relapsed or refractory CD22-positive B cell Acute lymphoblastic leukaemia (ALL)
50	Interferon	Paediatrics	Chronic granulomatous disease
51	Ixekizumab	Dermatology	Severe psoriasis
52a	Lenalidomide [#]	Haematology	Multiple myeloma (MM)
52b	Lenalidomide ^{^#} and Bortezomib [^]		
20c			
53	Lenvatinib [#]	Oncology	Unresectable hepatocellular carcinoma (HCC)
54	Letermovir	Haematology	Prophylaxis of cytomegalovirus reactivation and disease in recipients of an allogeneic haematopoietic stem cell transplant
55	Mepolizumab	Respiratory Medicine	Severe refractory eosinophilic asthma (add-on treatment)
56	Midostaurin [#]	Haematology	Acute myeloid leukaemia (AML)
57	Natalizumab	Neurology	Relapsing-remitting multiple sclerosis (RRMS)

Item	Drug	Specialties	Clinical indications
58a	Nilotinib	Haematology	Dasatinib-resistant chronic myeloid leukaemia (CML)
58b			Imatinib-resistant chronic myeloid leukaemia (CML)
58c			Newly diagnosed chronic myeloid leukaemia (CML) in chronic phase
59a	Nintedanib (Ofev)	Respiratory Medicine	Idiopathic pulmonary fibrosis (IPF)
59b		Rheumatology [^]	Rheumatic disease associated progressive fibrosing interstitial lung disease (PF-ILD) [^]
60a	Nivolumab	Oncology	Unresectable or metastatic melanoma
60b			Adjuvant treatment of melanoma with involvement of lymph nodes or metastatic disease, have undergone complete resection
60c			EGFR-ve and ALK-ve metastatic non-small cell lung cancer (NSCLC) progressed on or following platinum-based chemotherapy
61a	Obinutuzumab	Haematology	Follicular lymphoma
61b			Chronic lymphocytic leukaemia (CLL)
62	Olaparib ^{#~}	Oncology [~]	Epithelial ovarian, fallopian tube or primary peritoneal cancer [~]
63a	Omalizumab	Respiratory Medicine	Severe persistent confirmed allergic IgE mediated asthma
63b		Clinical Immunology	Chronic spontaneous urticaria
64a	Osimertinib [#]	Oncology	Locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC) (Progressed after previous treatment with an EGFR tyrosine kinase inhibitor (TKI))
64b			EGFR mutation positive non-small cell lung cancer (NSCLC) with CNS metastases (First-line treatment) [~]

Item	Drug	Specialties	Clinical indications
65	Paclitaxel (Albumin)^	Oncology^	Pancreatic cancer^
66	Palbociclib#	Oncology	HR positive HER2 negative locally advanced or metastatic breast cancer (MBC)
67	Panitumumab	Oncology	RAS wild-type colorectal cancer
68	Pazopanib	Oncology	Advanced renal cell carcinoma
69a	Pembrolizumab	Oncology	First-line treatment for metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression with no EGFR or ALK genomic tumor aberrations
69b			Bladder cancer~
70	Pertuzumab and Trastuzumab	Oncology	HER2 over-expressed metastatic breast cancer (MBC)
71a			HER2 positive, locally advanced, inflammatory, or early stage breast cancer
72a	Plerixafor	Haematology	Multiple myeloma (MM)
72b			Non-Hodgkin's lymphoma (NHL)
73	Pomalidomide#	Haematology	Multiple myeloma (MM)
74a	Ponatinib	Haematology	Acute lymphoblastic leukaemia (ALL)
74b			Chronic myeloid leukaemia (CML)
75a	Ranibizumab	Ophthalmology	Neovascular (wet) age-related macular degeneration
75b			Macular oedema secondary to Central Retinal Vein Occlusion
75c			Visual impairment caused by diabetic macular oedema
76a	Ribociclib#	Oncology	HR positive HER2 negative locally advanced or metastatic breast cancer (MBC)
76b	Ribociclib# and Fulvestrant		
3			
77a	Risankizumab	Dermatology	Severe psoriasis
77b		Rheumatology^	Psoriatic arthritis^
78a	Rituximab	Dermatology^	Pemphigus vulgaris^

Item	Drug	Specialties	Clinical indications
78b		Haematology	Maintenance therapy for relapsed follicular lymphoma (RFL)
78c			Previously-untreated and relapsed / refractory chronic lymphocytic leukaemia (CLL)
78d		Oncology	Malignant lymphoma (ML)
78e		Paediatrics	Severe, active granulomatosis with polyangiitis (GPA)/microscopic polyangiitis (MPA)
78f			CD20 positive diffuse large B-cell lymphoma, Burkitt lymphoma / Burkitt leukaemia or Burkitt-like lymphoma
78g		Rheumatology	Refractory rheumatoid arthritis (RRA)
78h			Severe, active non-life-threatening granulomatosis with polyangiitis/microscopic polyangiitis
79a		Ruxolitinib [#]	Haematology
79b	Graft versus host disease [^]		
80	Sarilumab	Rheumatology	Rheumatoid arthritis
81a	Secukinumab	Dermatology / Paediatrics [^]	Severe psoriasis
81b			Rheumatology
81c		Psoriatic arthritis	
82	Siltuximab	Haematology	Multicentric Castleman's disease (MCD)
83	Siponimod	Neurology	Secondary progressive multiple sclerosis (SPMS)
84	Sunitinib	Oncology	Gastrointestinal tumour
85	Temozolomide	Oncology	Recurrent high grade glioma
86a	Tocilizumab	Paediatrics	Juvenile idiopathic arthritis(JIA)
86b			Systemic juvenile idiopathic arthritis (JIA)
86c		Rheumatology	Refractory giant cell arteritis
86d			Rheumatoid arthritis
87a	Tofacitinib	Rheumatology	Rheumatoid arthritis

Item	Drug	Specialties	Clinical indications
87b			Psoriatic arthritis
88	Tolvaptan (Jinarc)	Nephrology	Autosomal dominant polycystic kidney disease (ADPKD)
71b	Trastuzumab	Oncology	HER2 over-expressed metastatic breast cancer (MBC)
71c			HER2 positive early breast cancer (EBC)
89a	Trastuzumab emtansine (T-DM1)	Oncology	HER2 positive early breast cancer (EBC)
89b			HER2 positive metastatic breast cancer (MBC)
90a	Upadacitinib	Rheumatology	Ankylosing spondylitis
90b			Psoriatic arthritis
90c			Rheumatoid arthritis
90d		Dermatology/ Paediatrics	Atopic dermatitis
91a	Ustekinumab	Dermatology	Severe psoriasis
91b		Rheumatology	Psoriatic arthritis
92 15d	Venetoclax [#] and Azacitidine	Haematology	Newly diagnosed acute myeloid leukaemia (AML)
93	Zanubrutinib ^{^#}	Haematology [^]	Waldenstrom's macroglobulinaemia (WM) [^]

Remarks:

[^] With effect from 25 May 2024.

~ **Abiraterone** for treating prostate cancer; **Olaparib** for treating epithelial ovarian/fallopian tube/ primary peritoneal cancer; **Osimeritinib** for treating lung cancer; and **Pembrolizumab** for treating bladder cancer, are repositioned from CCF Medical Assistance Programme (First Phase Programme) to SF with effect from 25 May 2024. New applications and renewal applications approved on or after the effective date will be subsidised by SF. For applications already approved before the effective date, CCF subsidy will be provided until end of treatment of the applications.

[#] The concerned drugs are under Capping Programmes where free drugs are subsequently provided through designated community pharmacies. For details, please refer to the [\[Information Sheet\]](#).

Self-financed Drugs supported by the Samaritan Fund (SF) and Community Care Fund (CCF) Medical Assistance Programme (First Phase Programme) (for specified self-financed cancer drugs)

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
Haematology	Acute lymphoblastic leukaemia	Dasatinib, Inotuzumab Ozogamicin, Ponatinib	✓	
	Acute myeloid leukaemia	Gilteritinib [#] , Midostaurin [#] , Venetoclax [#] and Azacitidine	✓	
		Gemtuzumab Ozogamicin		✓
	Chronic immune thrombocytopenia	Eltrombopag	✓	
	Chronic lymphocytic leukaemia	Acalabrutinib ^{**} , Bendamustine, Ibrutinib ^{**} , Obinutuzumab, Rituximab	✓	
	Chronic myeloid leukaemia	Dasatinib, Nilotinib, Ponatinib	✓	
	Classical Hodgkin Lymphoma (cHL)	Pembrolizumab [*]		✓
	Diffuse large B-cell lymphoma (DLBCL)	Polatuzumab Vedotin and Rituximab [^] , Polatuzumab Vedotin and Rituximab and Bendamustine		✓
	Follicular lymphoma	Obinutuzumab, Rituximab	✓	
	Graft versus host disease [^]	Ruxolitinib ^{^#}	✓	
	Mantle cell lymphoma	Ibrutinib ^{**}	✓	
Acalabrutinib ^{**}			✓	

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Multicentric Castleman's disease (MCD)	Siltuximab	✓	
	Multiple myeloma	Bortezomib*, Carfilzomib, Lenalidomide*#, Lenalidomide^*# and Bortezomib^*, Pomalidomide #	✓	
		Daratumumab* and Bortezomib*, Daratumumab^* and Lenalidomide^*#, Isatuximab and Pomalidomide#, Ixazomib# and Lenalidomide*#		✓
	Multiple myeloma / Non-Hodgkin's lymphoma	Plerixafor	✓	
	Myelodysplastic syndromes / chronic myelomonocytic leukaemia / acute myeloid leukaemia	Azacitidine	✓	
	Myelofibrosis-related splenomegaly or symptoms	Ruxolitinib#	✓	
	Paroxysmal nocturnal haemoglobinuria	Eculizumab	✓	
	Prophylaxis of cytomegalovirus reactivation and disease in recipients of an allogeneic haematopoietic stem cell transplant	Letermovir	✓	
	Severe aplastic anaemia	Eltrombopag#	✓	

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Systemic AL amyloidosis	Daratumumab* and Bortezomib*	✓	
	Systemic anaplastic large cell lymphoma (sALCL)	Brentuximab Vedotin	✓	
	CD30+ Hodgkin lymphoma/ CD30+ cutaneous T-cell lymphoma	Brentuximab Vedotin	✓	
	Waldenström's macroglobulinaemia (WM)	Ibrutinib**		✓
		Zanubrutinib^**	✓	✓
Respiratory Medicine	Idiopathic pulmonary fibrosis	Nintedanib (Ofev)	✓	
	Severe persistent confirmed allergic IgE mediated asthma	Omalizumab	✓	
	Severe refractory eosinophilic asthma	Mepolizumab, Benralizumab	✓	
	Severe asthma with Type 2 inflammation	Dupilumab	✓	
Rheumatology	Ankylosing spondylitis	Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab, Secukinumab, Upadacitinib	✓	
	Rheumatic disease associated progressive fibrosing interstitial lung disease (PF-ILD)^	Nintedanib(Ofev)^	✓	

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Psoriatic arthritis	Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Guselkumab, Infliximab, Risankizumab^, Secukinumab, Tofacitinib, Updacitinib, Ustekinumab	✓	
	Rheumatoid arthritis	Abatacept, Adalimumab, Baricitinib, Certolizumab Pegol, Etanercept, Golimumab, Infliximab, Sarilumab, Tocilizumab, Tofacitinib, Upadacitinib	✓	
	Refractory rheumatoid arthritis	Rituximab	✓	
	Refractory giant cell arteritis	Tocilizumab	✓	
	Severe, active non-life-threatening granulomatosis with polyangiitis / microscopic polyangiitis	Rituximab	✓	
	Systemic lupus erythematosus (SLE)	Anifrolumab^, Belimumab	✓	
Nephrology	Autosomal dominant polycystic kidney disease	Tolvaptan (Jinarc)	✓	

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
Neurology	Relapsing remitting multiple sclerosis	Cladribine, Natalizumab	✓	
	Secondary progressive multiple sclerosis (SPMS)	Siponimod	✓	
Oncology	Bladder cancer	Avelumab		✓
		Pembrolizumab*~	✓	
	Breast cancer	Abemaciclib [#] , Abemaciclib [#] and Fulvestrant, Everolimus [#] , Palbociclib [#] , Pertuzumab and Trastuzumab, Ribociclib [#] , Ribociclib [#] and Fulvestrant, Trastuzumab*, Trastuzumab emtansine	✓	
		Lapatinib, Neratinib		✓
	Colorectal cancer	Cetuximab, Panitumumab	✓	
		Bevacizumab		✓
	Endometrial cancer [^]	Lenvatinib ^{^*#} and Pembrolizumab ^{^*}		✓
	Gastric carcinoma	Trastuzumab*		✓
	Gastric, gastroesophageal junction or esophageal adenocarcinoma	Nivolumab*		✓
	Gastrointestinal tumour	Sunitinib*	✓	
Head and neck cancer	Nivolumab* Pembrolizumab*		✓	

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Recurrent high grade glioma	Temozolomide	✓	
	Liver cancer	Lenvatinib**	✓	
		Atezolizumab* and Bevacizumab		✓
	Lung cancer	Afatinib, Alectinib#, Atezolizumab*, Brigatinib#, Ceritinib#, Crizotinib#, Durvalumab, Gefitinib, Nivolumab*, Osimertinib**, Pembrolizumab*	✓	
		Atezolizumab*, Lorlatinib, Nivolumab* and Ipilimumab, Osimertinib^**, Pembrolizumab*		✓
	Malignant lymphoma	Rituximab	✓	
	Ovarian cancer	Pegylated Liposomal Doxorubicin		✓
	Epithelial ovarian / fallopian tube / primary peritoneal cancer	Bevacizumab, Niraparib#		✓
		Olaparib~#	✓	
	Pancreatic cancer^	Paclitaxel (Albumin)^	✓	
	Prostate cancer	Abiraterone#, Apalutamide#, Enzalutamide#	✓	
	Renal cell carcinoma	Axitinib#, Pazopanib	✓	

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
		Nivolumab* and Ipilimumab, Sunitinib*		✓
	Skin cancer	Dabrafenib** and Trametinib**, Nivolumab*	✓	
		Dabrafenib** and Trametinib**, Vemurafenib		✓
	Thyroid cancer	Lenvatinib**		✓
Ophthalmology	Macular oedema secondary to Central Retinal Vein Occlusion	Aflibercept, Ranibizumab	✓	
	Neovascular (wet) age-related macular degeneration	Aflibercept, Faricimab^, Ranibizumab	✓	
	Non-infectious intermediate, posterior and panuveitis	Adalimumab	✓	
	Paediatric chronic non-infectious anterior uveitis	Adalimumab	✓	
	Visual impairment caused by diabetic macular oedema	Aflibercept, Faricimab^, Ranibizumab	✓	
Endocrinology	Dwarfism	Growth Hormone	✓	
Dermatology	Atopic dermatitis	Abrocitinib^, Dupilumab, Upadacitinib	✓	
	Hidradenitis suppurativa	Adalimumab	✓	
	Pemphigus vulgaris^	Rituximab^	✓	

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Severe psoriasis	Adalimumab, Etanercept, Guselkumab, Infliximab, Ixekizumab, Risankizumab, Secukinumab, Ustekinumab	✓	
Clinical Immunology	Chronic spontaneous urticaria	Omalizumab	✓	
Paediatrics	Atopic dermatitis	Dupilumab, Upadacitinib	✓	
	CD20 positive diffuse large B-cell lymphoma, Burkitt lymphoma / Burkitt leukaemia or Burkitt-like lymphoma	Rituximab	✓	
	Classical Hodgkin Lymphoma (cHL)	Pembrolizumab*		✓
	Chronic granulomatous disease	Interferon	✓	
	Cryopyrin-associated periodic syndromes	Canakinumab	✓	
	Familial Mediterranean fever	Canakinumab	✓	
	Hyperimmunoglobulin D syndrome / mevalonate kinase deficiency	Canakinumab	✓	
	Neurofibromatosis^	Selumetinib^		✓
	Tumour necrosis factor receptor associated periodic syndrome	Canakinumab	✓	

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Severe, active granulomatosis with polyangiitis (GPA) / microscopic polyangiitis (MPA)	Rituximab	✓	
	Juvenile Idiopathic Arthritis	Abatacept, Adalimumab, Etanercept, Tocilizumab	✓	
	Hidradenitis suppurativa	Adalimumab	✓	
	Severe psoriasis	Adalimumab, Secukinumab [^]	✓	
	Systemic lupus erythematosus (SLE)	Belimumab	✓	
	Systemic juvenile idiopathic arthritis	Canakinumab, Tocilizumab	✓	

Remarks:

[^] With effect from 25 May 2024.

* The designated clinical indications of the same drug supported by different funds are different. Please consult your case doctor for details.

~ **Abiraterone** for treating prostate cancer; **Olaparib** for treating epithelial ovarian/fallopian tube/ primary peritoneal cancer; **Osimeritinib** for treating lung cancer; **Pembrolizumab** for treating bladder cancer, are repositioned from CCF Medical Assistance Programme (First Phase Programme) to SF with effect from 25 May 2024. New applications and renewal applications approved on or after the effective date will be subsidised by SF. For applications already approved before the effective date, CCF subsidy will be provided until end of treatment of the applications.

The concerned drugs are under Capping Programmes where free drugs are subsequently provided through designated community pharmacies. For details, please refer to the [\[Information Sheet\]](#).

Patients who have financial difficulties may apply for assistance from the Fund. Eligible applicants may be given full or partial assistance of the treatment cost, depending on their financial situation

For details of drugs covered by the CCF Medical Assistance Programmes, namely the First Phase Programme and the “Subsidy for Eligible Patients to Purchase Ultra-expensive Drugs (Including Those for Treating Uncommon Disorders)”, please refer to the [CCF Medical Assistance Programmes](#) web page in the Hospital Authority Website.